在ASH 2025年会上,吉利德旗下Kite Pharma公布Anito-cel(anitocabtagene autoleucel)在iMMagine-1 II期试验中的更新数据,该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤(R/R MM)患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率,中位随访15.9个月,缓解持续。无延迟神经毒性(包括无帕金森样症状、无颅...
Source Link在ASH 2025年会上,吉利德旗下Kite Pharma公布Anito-cel(anitocabtagene autoleucel)在iMMagine-1 II期试验中的更新数据,该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤(R/R MM)患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率,中位随访15.9个月,缓解持续。无延迟神经毒性(包括无帕金森样症状、无颅...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.